recombinant il 2  (ZeptoMetrix corporation)

Journal:

Article Title: A Phase I/II Study of Chemotherapy Followed by Donor Lymphocyte Infusion plus Interleukin-2 for Relapsed Acute Leukemia after Allogeneic Hematopoietic Cell Transplantation

doi: 10.1016/j.bbmt.2011.01.004

Figure Lengend Snippet: Outcomes after DLI plus IL-2 Therapy

Article Snippet: Recombinant IL-2 (Aldesleukin, Chiron, CA) was mixed in 500 ml 5% dextrose in water containing 0.1% human serum albumin and administered by 24-hour continuous intravenous infusion (CIV) daily for 5 days in the induction phase, using an ambulatory infusion pump starting immediately after DLI or on the following day.

Techniques:

Journal:

Article Title: A Phase I/II Study of Chemotherapy Followed by Donor Lymphocyte Infusion plus Interleukin-2 for Relapsed Acute Leukemia after Allogeneic Hematopoietic Cell Transplantation

doi: 10.1016/j.bbmt.2011.01.004

Figure Lengend Snippet: Outcomes after DLI plus IL-2 Therapy

Article Snippet: IL-2 administration Recombinant IL-2 (Aldesleukin, Chiron, CA) was mixed in 500 ml 5% dextrose in water containing 0.1% human serum albumin and administered by 24-hour continuous intravenous infusion (CIV) daily for 5 days in the induction phase, using an ambulatory infusion pump starting immediately after DLI or on the following day.

Techniques: